Nachum Kaplan
Corporate Officer/Principal bei Tel-Aviv University
Profil
Nachum Kaplan currently works at Tel-Aviv University, as Member from 1989.
Dr. Kaplan also formerly worked at Affinium Pharmaceuticals Ltd., as Vice President-Microbiology from 2002 to 2013.
Dr. Kaplan received his doctorate degree from Tel-Aviv University.
Aktive Positionen von Nachum Kaplan
Unternehmen | Position | Beginn |
---|---|---|
Tel-Aviv University
Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | Corporate Officer/Principal | 21.04.2010 |
Ehemalige bekannte Positionen von Nachum Kaplan
Unternehmen | Position | Ende |
---|---|---|
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Nachum Kaplan
Tel-Aviv University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |